AU7408200A - Mycophenolate mofetil in association with peg-ifn-alpha - Google Patents

Mycophenolate mofetil in association with peg-ifn-alpha Download PDF

Info

Publication number
AU7408200A
AU7408200A AU74082/00A AU7408200A AU7408200A AU 7408200 A AU7408200 A AU 7408200A AU 74082/00 A AU74082/00 A AU 74082/00A AU 7408200 A AU7408200 A AU 7408200A AU 7408200 A AU7408200 A AU 7408200A
Authority
AU
Australia
Prior art keywords
ifn
peg
prodrug
effective amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74082/00A
Other languages
English (en)
Inventor
Mary Catherine Graves
Stephen Christopher Pappas
Friederike Zahm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU7408200A publication Critical patent/AU7408200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU74082/00A 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha Abandoned AU7408200A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08
US60187907 2000-03-08
PCT/EP2000/007666 WO2001012214A2 (fr) 1999-08-13 2000-08-08 Mofetilmycophenolate associe a peg-ifn-alpha

Publications (1)

Publication Number Publication Date
AU7408200A true AU7408200A (en) 2001-03-13

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74082/00A Abandoned AU7408200A (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha

Country Status (14)

Country Link
EP (1) EP1220683A2 (fr)
JP (1) JP2003507339A (fr)
CN (1) CN1368887A (fr)
AU (1) AU7408200A (fr)
BR (1) BR0013252A (fr)
CA (1) CA2380653A1 (fr)
HU (1) HUP0202525A3 (fr)
MX (1) MXPA02001296A (fr)
PE (1) PE20010490A1 (fr)
PL (1) PL357367A1 (fr)
RU (1) RU2002105485A (fr)
TR (1) TR200200401T2 (fr)
WO (1) WO2001012214A2 (fr)
ZA (1) ZA200200280B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
KR20070045244A (ko) * 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010110503A1 (fr) * 2009-03-27 2010-09-30 주식회사 중외제약 Protéine fusionnée d'interféron-α (ifn-α) comprenant l'ifn-α et un peptide de transduction cytoplasmique (ctp)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (fr) 2011-10-21 2013-06-12 Abbvie Inc. Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
EP3215193B1 (fr) * 2014-11-06 2023-10-04 PharmaEssentia Corporation Régime posologique pour l'interféron pégylé
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
WO2001012214A2 (fr) 2001-02-22
JP2003507339A (ja) 2003-02-25
ZA200200280B (en) 2003-04-11
HUP0202525A2 (hu) 2002-11-28
BR0013252A (pt) 2002-04-16
CA2380653A1 (fr) 2001-02-22
CN1368887A (zh) 2002-09-11
WO2001012214A3 (fr) 2001-10-04
PE20010490A1 (es) 2001-04-27
TR200200401T2 (tr) 2002-06-21
HUP0202525A3 (en) 2003-11-28
MXPA02001296A (es) 2002-07-22
EP1220683A2 (fr) 2002-07-10
RU2002105485A (ru) 2004-01-27
PL357367A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
RU2271217C2 (ru) ПРИМЕНЕНИЕ ПЭГ-ИНТЕРФЕРОНА-α(ПЭГ-IFN-α) И РИБАВИРИНА ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
AU7408200A (en) Mycophenolate mofetil in association with peg-ifn-alpha
US20010046957A1 (en) Method for treating hepatitis C
US20080317714A1 (en) Method of Treating Hepatitis B Viral Infection
AU746648B2 (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
US8217014B2 (en) Pharmaceutical composition for treatment of blood clotting disorder
US20150147295A1 (en) Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013144193A1 (fr) Thérapie combinée destinée au traitement d'une infection par le vhc dans une sous-population de sous-génotype de patients spécifique
MXPA00011665A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 23, PAGE(S) 4878-4881 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 65863/00, 70124/00 AND 74082/00